S1507: Phase II study of docetaxel and trametinib in patients with G12C or non-G12C <i>KRAS</i> mutation positive (+) recurrent non-small cell lung cancer (NSCLC).
Shirish M. Gadgeel(Chinese University of Hong Kong), Karen Kelly(Cancer Research Center), Wallace Akerley(University of Utah), Gregory J. Gerstner(Illinois CancerCare), Asma Taj(St. Mary's Medical Center), David R. Gandara(University of California, Davis), Timothy F. Burns(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Konstantin H. Dragnev(Dartmouth Cancer Center), Jieling Miao(Fred Hutch Cancer Center), James Moon(University of Michigan), Jonathan W. Riess(University of California Davis Medical Center), Philip C. Mack(UC Davis Comprehensive Cancer Center)
Cited by 17
Related Papers
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2008|3.2k
Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2017|2.4k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k